Harrow, Inc. (HROW) stock
HROWNasdaqPharmaceutical PreparationsFiscal year ends December 31
$30.12+1.82 (+6.43%)
Close on Nov 13, 2026Market cap $1.13BP/E –Yield –
Harrow ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Harrow's ebitda for the twelve months ending Sep 30, 2026 was -$4.80M, down 116.4% year over year. For fiscal 2025 it was $31.83M, up 215.4% from the year before. The highest annual figure on record is $31.83M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.83M | +215.4% |
| FY2024 | Dec 31, 2024 | $10.09M | +579.1% |
| FY2023 | Dec 31, 2023 | $1.49M | -53.2% |
| FY2022 | Dec 31, 2022 | $3.17M | -0.7% |
| FY2021 | Dec 31, 2021 | $3.19M | +53.0% |
| FY2020 | Dec 31, 2020 | $2.09M | – |
| FY2019 | Dec 31, 2019 | -$2.86M | – |
| FY2018 | Dec 31, 2018 | -$3.61M | – |
| FY2017 | Dec 31, 2017 | -$10.76M | – |
| FY2016 | Dec 31, 2016 | -$14.83M | – |
| FY2015 | Dec 31, 2015 | -$14.57M | – |
| FY2014 | Dec 31, 2014 | -$10.11M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $11.92M | -20.9% |
| Q2 FY2026 | Jun 30, 2026 | -$10.55M | -189.7% |
| Q1 FY2026 | Mar 31, 2026 | -$21.63M | – |
| Q4 FY2025 | Dec 31, 2025 | $15.46M | +16.9% |
| Q3 FY2025 | Sep 30, 2025 | $15.07M | +801.5% |
| Q2 FY2025 | Jun 30, 2025 | $11.76M | +542.1% |
| Q1 FY2025 | Mar 31, 2025 | -$10.77M | – |
| Q4 FY2024 | Dec 31, 2024 | $13.22M | – |
| Q3 FY2024 | Sep 30, 2024 | $1.67M | -22.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.83M | -35.0% |
| Q1 FY2024 | Mar 31, 2024 | -$6.63M | -562.2% |
| Q4 FY2023 | Dec 31, 2023 | -$4.92M | – |
| Q3 FY2023 | Sep 30, 2023 | $2.15M | +1304.6% |
| Q2 FY2023 | Jun 30, 2023 | $2.82M | +33.3% |
| Q1 FY2023 | Mar 31, 2023 | $1.44M | -43.1% |
| Q4 FY2022 | Dec 31, 2022 | -$1.62M | – |
| Q3 FY2022 | Sep 30, 2022 | $153.00K | – |
| Q2 FY2022 | Jun 30, 2022 | $2.11M | -53.9% |
| Q1 FY2022 | Mar 31, 2022 | $2.52M | -25.5% |
| Q4 FY2021 | Dec 31, 2021 | -$1.45M | -149.1% |
| Q3 FY2021 | Sep 30, 2021 | -$3.32M | -261.0% |
| Q2 FY2021 | Jun 30, 2021 | $4.58M | – |
| Q1 FY2021 | Mar 31, 2021 | $3.38M | – |
| Q4 FY2020 | Dec 31, 2020 | $2.95M | +97.1% |
| Q3 FY2020 | Sep 30, 2020 | $2.06M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.75M | – |
| Q1 FY2020 | Mar 31, 2020 | -$180.00K | – |
| Q4 FY2019 | Dec 31, 2019 | $1.50M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.00M | – |
| Q2 FY2019 | Jun 30, 2019 | -$276.00K | – |
| Q1 FY2019 | Mar 31, 2019 | -$166.00K | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.78M | – |
| Q3 FY2018 | Sep 30, 2018 | -$226.00K | – |
| Q2 FY2018 | Jun 30, 2018 | -$223.00K | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.38M | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.79M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.38M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.70M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.89M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.15M | – |
See a number that looks wrong?